<DOC>
	<DOCNO>NCT01825785</DOCNO>
	<brief_summary>This multicenter , randomize , double-blind , placebo-controlled , ascend multiple dose study ass safety , tolerability , pharmacokinetics , pharmacodynamics subcutaneous administration 6 dose 1 mg/kg AMG 785 every 2 week 3 dos 3 mg/kg AMG 785 every 4 week healthy men postmenopausal woman low bone mass 3 dose 2 mg/kg AMG 785 every 4 week 6 dos 2 mg/kg AMG 785 every 2 week healthy postmenopausal woman low bone mass .</brief_summary>
	<brief_title>A Multiple Dose Study Evaluate Safety , Tolerability , Pharmacokinetics Pharmacodynamics AMG 785</brief_title>
	<detailed_description />
	<mesh_term>Bone Diseases , Metabolic</mesh_term>
	<criteria>Healthy male females 45 80 year age Postmenopausal females Low bone mineral density 25hydroxyvitamin D ≥ 20 ng/mL Weight ≤ 98 kg ( 216 lb ) and/or height ≤ 196 cm ( 77 ) Osteoporosis Subjects few 2 evaluable ( DXA ) vertebra ; metal hip bilaterally would allow least one evaluable ( DXA ) hip ; metal forearm bilaterally would allow least one evaluable ( DXA ) forearm Previous exposure AMG 785</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>